Zevra Therapeutics (NASDAQ:ZVRA) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Zevra Therapeutics (NASDAQ:ZVRA) released its earnings results on Monday. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.14, FiscalAI reports. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. The firm had revenue of $34.13 million during the quarter, compared to analyst estimates of $28.05 million.

Zevra Therapeutics Stock Up 1.6%

Shares of NASDAQ ZVRA traded up $0.14 during midday trading on Monday, hitting $9.12. The stock had a trading volume of 990,773 shares, compared to its average volume of 861,176. The business’s 50 day moving average is $8.80 and its 200-day moving average is $9.07. The company has a market cap of $513.44 million, a P/E ratio of 19.40 and a beta of 0.91. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The company has a quick ratio of 8.57, a current ratio of 8.62 and a debt-to-equity ratio of 0.46.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZVRA. HC Wainwright set a $26.00 price objective on Zevra Therapeutics in a research report on Tuesday, December 30th. Weiss Ratings reissued a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.80.

Insider Activity

In related news, insider Adrian W. Quartel sold 4,533 shares of the firm’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $8.83, for a total transaction of $40,026.39. Following the completion of the sale, the insider owned 9,723 shares of the company’s stock, valued at $85,854.09. This trade represents a 31.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total transaction of $27,540.00. Following the completion of the transaction, the senior vice president owned 29,590 shares of the company’s stock, valued at approximately $271,636.20. The trade was a 9.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 114,158 shares of company stock worth $1,062,878 over the last three months. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in shares of Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after buying an additional 8,552 shares during the last quarter. Creative Planning bought a new stake in Zevra Therapeutics during the second quarter valued at approximately $92,000. Qube Research & Technologies Ltd bought a new stake in Zevra Therapeutics during the second quarter valued at approximately $99,000. Finally, Quarry LP purchased a new stake in Zevra Therapeutics during the third quarter valued at approximately $103,000. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.